Reposted by Rashmi K. Murthy, MD MBE
Now in Nature Cancer!
@rkmurthy.bsky.social and colleagues provide evidence suggesting clinical benefit with the combination of tucatinib, capecitabine and trastuzumab as systemic regimen for women with HER2+ leptomeningeal metastasis
www.nature.com/articles/s43...
nature.com
Tucatinib–trastuzumab–capecitabine for treatment of leptomeningeal metastasis in women with HER2+ breast cancer: TBCRC049 phase 2 study results - Nature Cancer
Murthy and colleagues discussed recent research on the effect of a tucanitib–trastuzumab–capecitabine regimen in patients with HER2+ breast cancer and leptomeningeal metastasis.
